Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?

@article{Silva2014CurrentMT,
  title={Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?},
  author={Jo{\~a}o Gabriel Silva and Carlos Henrique da Silva and Francisco J. G{\'o}mez-de la Cruz},
  journal={Current opinion in urology},
  year={2014},
  volume={24 1},
  pages={
          21-8
        }
}
PURPOSE OF REVIEW The pharmacological treatment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) is based on alpha-blockers and 5α-reductase inhibitors isolated or in combination. Silodosin, an alpha-1A specific alpha-blocker is the only innovation in these groups of agents. This classical paradigm is being challenged by antimuscarinics, 5-phosphodiesterase inhibitors (PDE5i) and β3-adrenoreceptor agonists. RECENT FINDINGS Silodosin is effective in… CONTINUE READING
Highly Cited
This paper has 25 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Effects of 5-alpha reductase inhibitors: new insights on benefits and harms.

Current opinion in urology • 2018
View 6 Excerpts
Highly Influenced